MannKind (MNKD) Projected to Post Quarterly Earnings on Thursday

MannKind (NASDAQ:MNKD) will likely be announcing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect MannKind to post earnings of ($0.01) per share and revenue of $99.85 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:00 AM ET.

MannKind Trading Down 0.5%

Shares of MNKD stock opened at $5.54 on Wednesday. MannKind has a 1-year low of $3.38 and a 1-year high of $6.51. The stock has a market cap of $1.70 billion, a price-to-earnings ratio of 55.40 and a beta of 0.84. The stock has a 50-day moving average of $5.71 and a 200-day moving average of $5.38.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MNKD. Truist Financial set a $9.00 target price on shares of MannKind in a research report on Monday, November 24th. Wall Street Zen upgraded MannKind from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Zacks Research cut MannKind from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 10th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of MannKind in a research report on Monday, January 26th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of MannKind in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.06.

Insider Buying and Selling at MannKind

In other MannKind news, CEO Michael Castagna sold 65,804 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $6.01, for a total value of $395,482.04. Following the completion of the sale, the chief executive officer directly owned 2,504,792 shares of the company’s stock, valued at approximately $15,053,799.92. This represents a 2.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Stuart A. Tross sold 47,006 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $6.33, for a total transaction of $297,547.98. Following the completion of the sale, the insider owned 985,007 shares of the company’s stock, valued at approximately $6,235,094.31. This trade represents a 4.55% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 262,846 shares of company stock valued at $1,546,840. Company insiders own 3.00% of the company’s stock.

Institutional Trading of MannKind

A number of hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC boosted its position in MannKind by 19.8% in the first quarter. AQR Capital Management LLC now owns 55,333 shares of the biopharmaceutical company’s stock worth $278,000 after purchasing an additional 9,160 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of MannKind by 3.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 210,565 shares of the biopharmaceutical company’s stock worth $1,059,000 after purchasing an additional 6,079 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of MannKind by 8.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 670,872 shares of the biopharmaceutical company’s stock worth $3,374,000 after buying an additional 53,202 shares during the last quarter. JPMorgan Chase & Co. grew its position in MannKind by 42.7% during the second quarter. JPMorgan Chase & Co. now owns 1,352,017 shares of the biopharmaceutical company’s stock valued at $5,057,000 after buying an additional 404,842 shares during the period. Finally, Prudential Financial Inc. increased its holdings in MannKind by 84.8% during the second quarter. Prudential Financial Inc. now owns 37,381 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 17,150 shares during the last quarter. 49.55% of the stock is currently owned by institutional investors.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.